ACP
VERV

Acuta Capital Partners’s Verve Therapeutics VERV Stock Holding History

Acuta Capital Partners’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-162,724
Closed -$744K – 36
2025
Q1 		$744K Buy
162,724
+2,524
+2% +$16.9K 0.86% 28
2024
Q4 		$904K Buy
160,200
+14,100
+10% +$79.5K 0.91% 28
2024
Q3 		$707K Buy
+146,100
New +$849K 0.57% 29

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acuta Capital Partners's VERV Position: Q2 2025 in Review

Acuta Capital Partners sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 162,724 shares — an estimated $744K sold.

Acuta Capital Partners first reported a position in VERV in Q3 2024 and held it in 3 quarters. The position peaked at $904K in Q4 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Acuta Capital Partners reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 162,724 Verve Therapeutics shares in Q2 2025, an estimated $744K.
  • Acuta Capital Partners first reported a position in Verve Therapeutics in Q3 2024 and held it in 3 quarters.
  • Acuta Capital Partners's Verve Therapeutics position peaked at $904K in Q4 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Acuta Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.